Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-B96 / ENGOT-ov65 pembrolizumab plus paclitaxel ± bevacizumab in platinum-resistant ovarian cancer
jRCT2051210184Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Apr 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, double-blind trial in epithelial ovarian cancer (EOC), fallopian tube cancer (PFTC), primary peritoneal cancer (PPC) and 1 more comparing Pembrolizumab arm with Placebo arm (2 arms). Primary endpoint: Progression-free survival (PFS) by investigator per RECIST 1.1. Started Apr 2022; status: active, not recruiting.
02
Drugs
03
Conditions
epithelial ovarian cancer (EOC)fallopian tube cancer (PFTC)primary peritoneal cancer (PPC)ovarian cancer
Beyond the preview
Go deeper on jRCT2051210184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051210184.